دورية أكاديمية
أعرض في EDS

C1R, CCL2, and TNFRSF1A Genes in Coronavirus Disease-COVID-19 Pathway Serve as Novel Molecular Biomarkers of GBM Prognosis and Immune Infiltration.

التفاصيل البيبلوغرافية
العنوان: C1R, CCL2, and TNFRSF1A Genes in Coronavirus Disease-COVID-19 Pathway Serve as Novel Molecular Biomarkers of GBM Prognosis and Immune Infiltration.
المؤلفون: Wang X; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Yang G; Department of Medical Genetics, School of Basic Medical Science, Demonstration Center for Experimental Basic Medicine Education, Wuhan University, 430071 Wuhan City, Hubei Province, China., Wang Q; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Zhao Y; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Ding K; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Ji C; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Shi Z; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Li H; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China., Li Y; Department of Medical Genetics, School of Basic Medical Science, Demonstration Center for Experimental Basic Medicine Education, Wuhan University, 430071 Wuhan City, Hubei Province, China., Li S; School of Life Science, Bengbu Medical College, 233030 Bengbu City, Anhui Province, China.
المصدر: Disease markers [Dis Markers] 2022 Jun 18; Vol. 2022, pp. 8602068. Date of Electronic Publication: 2022 Jun 18 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-
مواضيع طبية MeSH: Brain Neoplasms*/pathology , COVID-19*/genetics , Chemokine CCL2*/genetics , Complement C1r*/genetics , Glioblastoma*/diagnosis , Glioblastoma*/pathology , Receptors, Tumor Necrosis Factor, Type I*/genetics, Biomarkers, Tumor/genetics ; Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Humans ; Prognosis
مستخلص: Glioblastoma multiforme (GBM) is a prevalent intracranial brain tumor associated with a high rate of recurrence and treatment difficulty. The prediction of novel molecular biomarkers through bioinformatics analysis may provide new clues into early detection and eventual treatment of GBM. Here, we used data from the GTEx and TCGA databases to identify 1923 differentially expressed genes (DEGs). GO and KEGG analyses indicated that DEGs were significantly enriched in immune response and coronavirus disease-COVID-19 pathways. Survival analyses revealed a significant correlation between high expression of C1R, CCL2, and TNFRSF1A in the coronavirus disease-COVID-19 pathway and the poor survival in GBM patients. Cell experiments indicated that the mRNA expression levels of C1R, CCL2, and TNFRSF1A in GBM cells were very high. Immune infiltration analysis revealed a significant difference in the proportion of immune cells in tumor and normal tissue, and the expression levels of C1R, CCL2, and TNFRSF1A were associated with immune cell infiltration of GBM. Additionally, the protein-protein interaction networks of C1R, CCL2, and TNFRSF1A involved a total of 65 nodes and 615 edges. These results suggest that C1R, CCL2, and TNFRSF1A may be used as molecular biomarkers of prognosis and immune infiltration in GBM patients in the future.
Competing Interests: The authors declare no competing interests.
(Copyright © 2022 Xianggang Wang et al.)
References: Curr Med Chem. 2017;24(27):3002-3009. (PMID: 28521700)
Front Mol Biosci. 2020 Oct 06;7:582911. (PMID: 33134320)
Emerg Microbes Infect. 2020 Dec;9(1):761-770. (PMID: 32228226)
Curr Oncol Rep. 2020 May 8;22(5):53. (PMID: 32385672)
J Virol. 2010 Aug;84(15):7703-12. (PMID: 20484496)
Front Genet. 2021 Jun 03;12:680528. (PMID: 34149816)
Int J Biol Sci. 2021 Jan 1;17(2):430-447. (PMID: 33613103)
J Rheumatol. 2015 Aug;42(8):1534-5. (PMID: 26233954)
Neoplasia. 2018 May;20(5):489-498. (PMID: 29621649)
J Transl Med. 2020 Jan 30;18(1):40. (PMID: 32000807)
J Neurooncol. 2021 Jan;151(1):3-12. (PMID: 32542437)
Int J Mol Sci. 2020 Apr 23;21(8):. (PMID: 32340320)
Int J Mol Sci. 2021 Feb 02;22(3):. (PMID: 33540898)
Int J Mol Sci. 2021 Aug 08;22(16):. (PMID: 34445235)
J Interferon Cytokine Res. 2009 Jun;29(6):313-26. (PMID: 19441883)
J Phys Chem Lett. 2021 Feb 25;12(7):1793-1802. (PMID: 33577324)
Mol Cancer. 2020 Feb 27;19(1):41. (PMID: 32103760)
Oncogene. 2016 Nov 10;35(45):5819-5825. (PMID: 27041580)
Front Immunol. 2020 Oct 20;11:585034. (PMID: 33193404)
J Cell Biochem. 2019 Jun;120(6):9522-9531. (PMID: 30506958)
Front Immunol. 2021 Nov 03;12:771210. (PMID: 34804061)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Cancer Med. 2020 Feb;9(3):1161-1172. (PMID: 31856409)
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (CCL2 protein, human)
0 (Chemokine CCL2)
0 (Receptors, Tumor Necrosis Factor, Type I)
0 (TNFRSF1A protein, human)
EC 3.4.21.41 (Complement C1r)
تواريخ الأحداث: Date Created: 20220621 Date Completed: 20220622 Latest Revision: 20220716
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9206210
DOI: 10.1155/2022/8602068
PMID: 35726234
قاعدة البيانات: MEDLINE
الوصف
تدمد:1875-8630
DOI:10.1155/2022/8602068